Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial

Abstract Treatment options for severe CRSwNP are limited. Dupilumab is a safe, well‐tolerated, and effective alternative in patients with poor control of symptoms, corticosteroid‐dependent disease, and high rates of recurrence of nasal polyps after surgery.

Bibliographic Details
Main Authors:	Matteo Trimarchi, Pietro Indelicato, Alessandro Vinciguerra, Mario Bussi
Format:	Article
Language:	English
Published:	Wiley 2021-03-01
Series:	Clinical Case Reports
Subjects:	anti–IL‐13 anti–IL‐4 biologic agents chronic rhinosinusitis dupilumab DUPIXENT
Online Access:	https://doi.org/10.1002/ccr3.3792

id	doaj-871bf4c26913447ea542092d2c91e66e
record_format	Article
spelling	doaj-871bf4c26913447ea542092d2c91e66e2021-03-21T09:11:40ZengWileyClinical Case Reports2050-09042021-03-01931428143210.1002/ccr3.3792Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trialMatteo Trimarchi0Pietro Indelicato1Alessandro Vinciguerra2Mario Bussi3Otorhinolaryngology Unit Division of Head and Neck Department IRCCS San Raffaele Scientific Institute Milano ItalyOtorhinolaryngology Unit Division of Head and Neck Department IRCCS San Raffaele Scientific Institute Milano ItalyOtorhinolaryngology Unit Division of Head and Neck Department IRCCS San Raffaele Scientific Institute Milano ItalyOtorhinolaryngology Unit Division of Head and Neck Department IRCCS San Raffaele Scientific Institute Milano ItalyAbstract Treatment options for severe CRSwNP are limited. Dupilumab is a safe, well‐tolerated, and effective alternative in patients with poor control of symptoms, corticosteroid‐dependent disease, and high rates of recurrence of nasal polyps after surgery.https://doi.org/10.1002/ccr3.3792anti–IL‐13anti–IL‐4biologic agentschronic rhinosinusitisdupilumabDUPIXENT
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Matteo Trimarchi Pietro Indelicato Alessandro Vinciguerra Mario Bussi
spellingShingle	Matteo Trimarchi Pietro Indelicato Alessandro Vinciguerra Mario Bussi Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial Clinical Case Reports anti–IL‐13 anti–IL‐4 biologic agents chronic rhinosinusitis dupilumab DUPIXENT
author_facet	Matteo Trimarchi Pietro Indelicato Alessandro Vinciguerra Mario Bussi
author_sort	Matteo Trimarchi
title	Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial
title_short	Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial
title_full	Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial
title_fullStr	Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial
title_full_unstemmed	Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial
title_sort	clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: the first case outside of a clinical trial
publisher	Wiley
series	Clinical Case Reports
issn	2050-0904
publishDate	2021-03-01
description	Abstract Treatment options for severe CRSwNP are limited. Dupilumab is a safe, well‐tolerated, and effective alternative in patients with poor control of symptoms, corticosteroid‐dependent disease, and high rates of recurrence of nasal polyps after surgery.
topic	anti–IL‐13 anti–IL‐4 biologic agents chronic rhinosinusitis dupilumab DUPIXENT
url	https://doi.org/10.1002/ccr3.3792
work_keys_str_mv	AT matteotrimarchi clinicalefficacyofdupilumabinthetreatmentofseverechronicrhinosinusitisthefirstcaseoutsideofaclinicaltrial AT pietroindelicato clinicalefficacyofdupilumabinthetreatmentofseverechronicrhinosinusitisthefirstcaseoutsideofaclinicaltrial AT alessandrovinciguerra clinicalefficacyofdupilumabinthetreatmentofseverechronicrhinosinusitisthefirstcaseoutsideofaclinicaltrial AT mariobussi clinicalefficacyofdupilumabinthetreatmentofseverechronicrhinosinusitisthefirstcaseoutsideofaclinicaltrial
_version_	1724211081872670720

Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial

Similar Items